SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Osnes L T N)
 

Search: WFRF:(Osnes L T N) > T-cell acute lympho...

  • Quist-Paulsen, P.Univ Trondheim Hosp, St Olavs Hosp, Dept Hematol, Trondheim, Norway. (author)

T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2019-10-14
  • Springer Science and Business Media LLC,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-409967
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409967URI
  • https://doi.org/10.1038/s41375-019-0598-2DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-169891URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143347418URI
  • https://gup.ub.gu.se/publication/286616URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD >= 5% on day 29 or >= 0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Toft, N.Univ Copenhagen, Herlev Univ Hosp, Dept Hematol, Herlev, Denmark. (author)
  • Heyman, M.Karolinska Institutet (author)
  • Abrahamsson, Jonas,1954Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics(Swepub:gu)xabrjo (author)
  • Griskevicius, L.Vilnius Univ, Vilnius Univ Hosp Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania. (author)
  • Hallböök, HeleneUppsala universitet,Hematologi(Swepub:uu)helehall (author)
  • Jonsson, O. G.Landspitali Univ Hosp, Childrens Hosp, Reykjavik, Iceland. (author)
  • Palk, K.North Estonia Med Ctr, Dept Hematol, Tallinn, Estonia. (author)
  • Vaitkeviciene, G.Vilnius Univ, Vilnius Univ Hosp Santariskiu Klinikos, Childrens Hosp, Ctr Pediat Oncol & Hematol, Vilnius, Lithuania. (author)
  • Vettenranta, K.Helsinki Univ Cent Hosp, Hosp Children & Adolescents, Div Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland. (author)
  • Asberg, A.Univ Trondheim Hosp, St Olavs Hosp, Dept Pediat, Trondheim, Norway. (author)
  • Frandsen, T. L.Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark. (author)
  • Opdahl, S.NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway. (author)
  • Marquart, H. V.Univ Hosp, Rigshosp, Dept Clin Immunol, Sect 7631, Copenhagen, Denmark.,Umea Univ, Dept Med Biosci Pathol, Umea, Sweden. (author)
  • Siitonen, S.Helsinki Univ Cent Hosp, Dept Clin Chem, Helsinki, Finland. (author)
  • Osnes, L. T.Oslo Univ Hosp, Dept Immunol, Oslo, Norway. (author)
  • Hultdin, MagnusUmeå universitet,Patologi(Swepub:umu)magn0001 (author)
  • Overgaard, U. M.Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark. (author)
  • Wartiovaara-Kautto, U.Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (author)
  • Schmiegelow, K.Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark.;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark. (author)
  • Univ Trondheim Hosp, St Olavs Hosp, Dept Hematol, Trondheim, Norway.Univ Copenhagen, Herlev Univ Hosp, Dept Hematol, Herlev, Denmark. (creator_code:org_t)

Related titles

  • In:Leukemia: Springer Science and Business Media LLC34:2, s. 347-3570887-69241476-5551

Internet link

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view